These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Garrison LP; Carlson RJ; Carlson JJ; Kuszler PC; Meckley LM; Veenstra DL Drug Metab Rev; 2008; 40(2):377-401. PubMed ID: 18464050 [TBL] [Abstract][Full Text] [Related]
3. Do patents impede the provision of genetic tests in Australia? Nicol D; Liddicoat J Aust Health Rev; 2013 Jun; 37(3):281-5. PubMed ID: 23702081 [TBL] [Abstract][Full Text] [Related]
5. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. Barton JH; Emanuel EJ JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422 [TBL] [Abstract][Full Text] [Related]
6. Emerging ethical issues in pharmacogenomics: from research to clinical practice. Freund CL; Wilfond BS Am J Pharmacogenomics; 2002; 2(4):273-81. PubMed ID: 12421098 [TBL] [Abstract][Full Text] [Related]
7. Expansion of pharmacogenomics into the community pharmacy: billing considerations. O'Connor SK; Michaels N; Ferreri S Pharmacogenomics; 2015; 16(3):175-80. PubMed ID: 25712181 [No Abstract] [Full Text] [Related]
8. An economic justification for open access to essential medicine patents in developing countries. Flynn S; Hollis A; Palmedo M J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066 [TBL] [Abstract][Full Text] [Related]
9. Impact of the US Patent System on the promise of personalized medicine. Solomon LM; Sieczkiewicz GJ Gend Med; 2007 Sep; 4(3):187-92. PubMed ID: 18022586 [TBL] [Abstract][Full Text] [Related]
10. Genetic testing, ethical concerns, and the role of patent law. Caulfield TA; Gold ER Clin Genet; 2000 May; 57(5):370-5. PubMed ID: 10852371 [TBL] [Abstract][Full Text] [Related]
11. Direct to confusion: lessons learned from marketing BRCA testing. Matloff E; Caplan A Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769 [TBL] [Abstract][Full Text] [Related]
12. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Suh DC; Manning WG; Schondelmeyer S; Hadsall RS Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475 [TBL] [Abstract][Full Text] [Related]
13. Will pharmacogenomics alter the role of patents in drug development? Eisenberg RS Pharmacogenomics; 2002 Sep; 3(5):571-4. PubMed ID: 12223043 [No Abstract] [Full Text] [Related]
14. Ethical and public policy challenges for pharmacogenomics. Gershon ES; Alliey-Rodriguez N; Grennan K Dialogues Clin Neurosci; 2014 Dec; 16(4):567-74. PubMed ID: 25733960 [TBL] [Abstract][Full Text] [Related]
16. Finding a liability-free space in which personalized medicine can bloom. Evans BJ Clin Pharmacol Ther; 2007 Oct; 82(4):461-5. PubMed ID: 17713468 [TBL] [Abstract][Full Text] [Related]
17. Legal, ethical, and conceptual bottlenecks to the development of useful genomic tests. Tomasson M Ann Health Law; 2009; 18(2):231-60, 8 p. preceding i. PubMed ID: 21950240 [TBL] [Abstract][Full Text] [Related]
18. Patent ruling expands access to genetic tests and treatments. Woodward C CMAJ; 2013 Aug; 185(11):E507-8. PubMed ID: 23798460 [No Abstract] [Full Text] [Related]
19. Israeli doctors want to stop European patent for genetic test. Siegel-Itzkovich J BMJ; 2005 Jul; 331(7507):8. PubMed ID: 15994669 [No Abstract] [Full Text] [Related]
20. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era. Evans BJ Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]